AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.375

+0.0051.35%

Volume:1.40M

Turnover:526.96K

Market Cap:552.65M

PE:-8.89

High:0.380

Open:0.370

Low:0.370

Close:0.370

52wk High:0.470

52wk Low:0.222

Shares:1.47B

Float Shares:1.23B

Volume Ratio:0.57

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.042

EPS(LYR):-0.042

ROE:-36.88%

ROA:-22.66%

PB:3.85

PE(LYR):-8.89

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies+1.74%

Capital Flow

Inflow:

Outflow:

News

Immutep Achieves 50% Enrolment in Global Tacti-004 (Keynote-F91) Phase Iii Trial in 1L Nsclc

THOMSON REUTERS

Immutep Reaches 50% Enrollment in TACTI‑004 Phase Three Lung Cancer Trial

MT Newswires Live

Immutep Receives AU$30 Million In Upfront Payment From Indian Drugmaker In January

MT Newswires Live

BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IMM.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.375,"timestamp":1770700320000,"preClose":0.37,"halted":0,"volume":1402062,"delay":0,"changeRate":0.013513513513513526,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.042199,"marketStatus":"Closed","change":0.005,"latestTime":"02-10 16:12:00 AEDT","open":0.37,"high":0.38,"low":0.37,"amount":526962,"amplitude":0.027027,"askPrice":0.39,"askSize":25000,"bidPrice":0.375,"bidSize":72863,"shortable":3,"etf":0,"ttmEps":-0.042199,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.37,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0.565696,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-22.66%","roe":"-36.88%","lyrEps":-0.042199,"volumeRatio":0.565696,"shares":1473721306,"dividePrice":0,"high":0.38,"amplitude":0.027027,"preClose":0.37,"low":0.37,"week52Low":0.222,"pbRate":"3.85","psRate":"109.57","week52High":0.47,"institutionHeld":0,"latestPrice":0.375,"committee":0.489082,"eps":-0.042199,"divideRate":0,"volume":1402062,"delay":0,"ttmEps":-0.042199,"open":0.37,"prevYearClose":0.415,"prevWeekClose":0.365,"prevMonthClose":0.395,"prevQuarterClose":0.415,"fiveDayClose":0.4,"twentyDayClose":0.435,"sixtyDayClose":0.27,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609459560","title":"Immutep Achieves 50% Enrolment in Global Tacti-004 (Keynote-F91) Phase Iii Trial in 1L Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2609459560","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609459560?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:00","pubTimestamp":1770382800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nTUA9XGGVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2609533421","title":"Immutep Reaches 50% Enrollment in TACTI‑004 Phase Three Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533421","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533421?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:21","pubTimestamp":1770333717,"startTime":"0","endTime":"0","summary":"Immutep  has achieved 50% of its patient enrollment target in the TACTI-004 phase three trial, testing eftilagimod alfa in combination with Merck's Keytruda and chemotherapy as a first-line therapy for advanced or metastatic non-small cell lung cancer, according to a Friday Australian bourse filing.The trial has enrolled 378 patients across more than 140 sites in 27 countries, per the filing.It seeks to increase response rates to anti-PD-1 therapy across all PD-L1 levels while improving clinical outcomes and patient survival, the filing said.Patient enrollment and the scheduled futility analysis are proceeding as planned, with complete enrollment anticipated by the third quarter, the filling added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2607779506","title":"Immutep Receives AU$30 Million In Upfront Payment From Indian Drugmaker In January","url":"https://stock-news.laohu8.com/highlight/detail?id=2607779506","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607779506?lang=en_us&edition=fundamental","pubTime":"2026-01-29 11:42","pubTimestamp":1769658172,"startTime":"0","endTime":"0","summary":"Immutep  said it received around AU$30 million in upfront payment from Indian firm Dr. Reddy's Laboratories in January under its strategic collaboration for the commercialization of Eftilagimod Alfa, its drug candidate for the treatment of non-small cell lung cancer, according to a Thursday Australian bourse filing.The firm is eligible to receive up to around AU$528 million in potential milestones, plus royalties on commercial sales of the drug candidate.During the December 2025 quarter, its AIPAC-003 phase two/three trial in metastatic breast cancer enrolled 71 metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative/low patients, resistant to endocrine therapy, including cyclin-dependent kinase 4/6 inhibitors, or triple-negative breast cancer patients.Its shares fell 2% in recent trading on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2593545170","title":"BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update","url":"https://stock-news.laohu8.com/highlight/detail?id=2593545170","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593545170?lang=en_us&edition=fundamental","pubTime":"2025-12-23 08:44","pubTimestamp":1766450664,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update** Shares of Australia's Immutep IMM.AX rise as much as 3.8% to A$0.415, their highest since September 13, 2024** Biotech fir","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT00R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":15,"pageCount":1,"totalSize":59,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IMM.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":0.017447}]}}